|
|
在研机构- |
|
在研适应症- |
非在研适应症- |
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
A prospective, interventional, randomized, double-blind, placebo-controlled study to evaluate the safety and effectiveness of IND02 capsules (Cinamuneâ?¢) in SARS-CoV2 positive patients with mild to moderate COVID-19, managed as per the Government of India COVID-19 management guidelines, at COVID-19 management centres offering integrated Ayurvedic care.
Evaluation of intranasal application of IND02 for the prophylaxis against SARS-COV-2 infections in moderate to high risk population: A double blind placebo-controlled clinical study (IND02)
Pilot experimental study for safety and efficacy of IND02 (standardized hydroalcoholic extract of Cinnamonum zeylanicum bark extract) in reducing symptoms of Seasonal Allergic Rhinitis.
100 项与 HIV envelope protein gp120 x APOBEC3G 相关的临床结果
100 项与 HIV envelope protein gp120 x APOBEC3G 相关的转化医学
0 项与 HIV envelope protein gp120 x APOBEC3G 相关的专利(医药)